Brief: Belite Bio Initiates Rolling Submission Of New Drug Application To The U.S. Food And Drug Administration For Tinlarebant For The Treatment Of Stargardt Disease
21/04/2026 22:48
April 21 (Reuters) - Belite Bio Inc BLTE.O: BELITE BIO INITIATES ROLLING SUBMISSION OF NEW DRUG APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR TINLAREBANT FOR THE TREATMENT OF STARGARDT DISEASE BELITE BIO INC - EXPECTS TO COMPLETE NDA ROLLING SUBMISSION IN Q2 2026 BELITE BIO INC - TINLAREBANT GRANTED BREAKTHROUGH THERAPY DESIGNATION BY FDA FOR STARGARDT DISEASE Source text: ID:nGNX66C3y3 Further company coverage: BLTE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Belite Bio
See all newsBrief: Belite Bio Announces Uplisting To The Nasdaq Global Select Market
Brief: Belite Bio Announces Multi-Market Submission Of Marketing Authorization Applications Via The Access Consortium Pathway For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Brief: Belite Bio Announces Submission Of New Drug Application To The Ministry Of Health, Labour, And Welfare In Japan Under The Sakigake Designation System For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Belite Bio, Inc reports results for the quarter ended June 30 - Earnings Summary
Belite Bio Q2 net loss widens on higher expenses